Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832295 | 0.98 | NPC1 (0.72) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31184151 | 0.98 | NPC1 (0.72) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1713999 | 0.85 | NPC1 (0.70) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL7694046 | 0.84 | NPC1 (0.51) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6350588 | 0.84 | CHRNB2 (0.62) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5910889 | 0.82 | NPC1 (0.57) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL24830044 | 0.82 | NPC1 (0.71) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2114532 | 0.82 | NPC1 (0.66) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31184229 | 0.82 | NPC1 (0.71) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL606857 | 0.82 | HRH4 (1.00) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458934-B | Quinoxaline compounds and application thereof | 米伦纽姆医药公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-106458934-A | Quinoxaline compounds and uses thereof | 米伦纽姆医药公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2015018797-A2 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2015-02-12 | — | — | WO | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| EP-0104445-A3 | PIPERIDINOQUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE | BOEHRINGER INGELHEIM KG (DE) | 1985-07-10 | — | — | EP | disclosed |
| EP-0104445-A2 | Piperidinoquinoxaline derivatives, their preparation and use | BOEHRINGER INGELHEIM KG (DE) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | NPC1 301/4885RAB9A 4315/4885MAPT 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.